If you or someone you know just got prescribed Rezdiffra, that new drug for MASH (formerly known as NASH), one thing quickly comes to mind: I wonder what it really costs once insurance gets involved? Because Rezdiffra isn’t cheap. The sticker price is high as well, and without coverage many patients have to pay thousands of dollars a month. But as soon as you begin to consider details of insurance plans, copay cards, specialty pharmacy requirements and discount programs — the real out-of-pocket cost becomes very different. “The difference between learning how ‘Rezdiffra cost with insurance’ works in 2026 and not could be whether that treatment is financially viable, or there’s an incredibly onerous burden associated with it,” he said.
Here’s what’s happening right now. The drugmaker has set a wholesale acquisition cost for Rezdiffra of approximately $47,400 per year before discounts. That’s a big number for anyone, whether they are paying out-of-pocket. Some pharmacies advertise a 30-day supply of 100 mg tablets for over $5,200 without insurance.
But when you have commercial insurance, the cost picture shifts — and at times, dramatically so. According to the official insurance-coverage guidance on Rezdiffra, available through manufacturer Corcept Therapeutics, the majority of commercially insured patients (about 87%) can obtain coverage for the drug and — with use of a copay-savings card from the manufacturer — may be able to receive it for as little as $10 per month. In a few cases, the copay-savings card reduces the cost of the test to nothing out of pocket per month.
That doesn’t mean all patients pay $10 or $0 — a variety of factors, including the specifics of your insurance plan, whether prior authorization is needed, whether you use a specialty pharmacy and whether you qualify for assistance programs determine cost. For others, insurance may pay only part of the cost, and you will be left with plenty out of pocket — especially if you are above a high deductible or in a coverage gap.
For uninsured patients or those whose insurance does not cover Rezdiffra, costs are still daunting. Single-source pharmacy pricing indicates that the cost for a 30-day supply (up to19 g/day) of the product can exceed $4,000—$5,200 depending on pharmacy and dosage.
But there are ways to mitigate the cost burden. Among the effective suggestions are taking advantage of the manufacturer’s copay-savings program (if you qualify), choosing a 90-day-supply or mail-order pharmacy if your insurance company allows, comparison shopping among specialty pharmacies, and keeping track of available patient assisutance programs.’s errand apps or is developing technology to let customers avoid cashiers at its stores.
Still, even with all of these tools at hand, many health economists say that the current price for Rezdiffra might not represent a cost-effective use of money on a large scale. The payer-based cost-effectiveness analysis of the drug in 2025, further assumed that it is “borderline” at an annual price of ca $19 011 and dubious with respect to value for money when calculated using wholesale prices. The editorial was accompanied by a breakdown of the numbers, which showed that long-term affordability — and access — is likely to depend to an unsustainable degree either on insurance companies footing much or most of the bill; on access-program discounts that could add up to 15 percent for those with high-deductible plans (rather than preventing free medicines, as The Times reported last week); or even on discounts from manufacturers if prices go drastically higher than they are now.
For patients and families attempting to budget finances, the most important thing is to assume Rezdiffra is a long-term commitment. Even if you pay little or nothing one month, insurance rules may change, a copay-card can expire and eligibility for assistance can shift. It’s also worth verifying whether your insurance company or contact does put Rezdiffra on its formulary and won’t demand additional paperwork or prior authorization to access, potentially delaying it forever.
Bottom line — the headline price for Rezdiffra is scary. But for many patients in 2026, “Rezdiffra cost with insurance” does not involve thousands of dollars a month. With the right insurance, copay assistance and pharmacy arrangement, many are paying only a nominal monthly copay — sometimes as little as $10 or nothing. For others, particularly the uninsured or underinsured, the price is still high.
The watchword is homework: Call your insurer, pharmacy and the manufacturer’s support program; look into these copay or discount programs; figure out specialty-pharmacy coverage; prepare for long-term adherence. Presentation because, in the year 2026, maybe Rezdiffra will be expensive for MASH patients — but insurance can also put it within reach.
